AEON Biopharma, Inc. (AEON)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Research and Development of ABP-450				2.52M	-	-
Alphaeon Credit				-	3.36M	2.42M
Alphaeon Credit Growth				-	38.89%	-
Total				2.52M	3.36M	2.42M
Total Growth				-24.99%	38.89%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
United States				2.52M	3.36M	2.42M
United States Growth				-24.99%	38.89%	-
Total				2.52M	3.36M	2.42M
Total Growth				-24.99%	38.89%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 22, 2026

Data Sources Report a data error